GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vebreltinib   Click here for help

GtoPdb Ligand ID: 11677

Synonyms: APL-101 | bozitinib | PLB1001
Approved drug PDB Ligand
vebreltinib is an approved drug
Compound class: Synthetic organic
Comment: We obtained the chemical structure for vebreltinib from WHO Proposed list 125 of July 2021. This mapped to PubChem CID 72202701. Synonyms for vebreltinib (from PubChem) include APL-101 and PLB-1001 [1]. Vebreltinib is an oral, ATP-competitive MET kinase inhibitor that is active against MET-altered tumour cells in preclinical models. It can cross the blood-brain barrier.

vebreltinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 78.72
Molecular weight 424.14
XLogP 5.93
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Cn1nc2c(c1)cc(c(c2)F)C(c1nnc2n1nc(cc2)c1cnn(c1)C1CC1)(F)F
Isomeric SMILES Cn1cc2cc(c(cc2n1)F)C(c1nnc2n1nc(cc2)c1cn(nc1)C1CC1)(F)F
InChI InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
InChI Key QHXLXUIZUCJRKV-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Vebreltinib (PLB-1001, APL-101) was advanced to clinical trials in a range of advanced solid tumour types. The Chinese drug regulator (NMPA) approved vebreltinib (Wanbirui®) in April 2024, to treat astrocytoma or glioblastoma with the IDH PTPRZ1-MET fusion gene alteration.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03175224 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2 Interventional Apollomics Inc.
NCT03655613 APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2 Interventional Apollomics (Australia) Pty. Ltd.
NCT04258033 A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation Phase 2 Interventional Beijing Pearl Biotechnology Limited Liability Company
NCT02978261 Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas Phase 1 Interventional Beijing Pearl Biotechnology Limited Liability Company